Intravenous Hydration Therapy Market By Service, By Component By End user : Global Opportunity Analysis and Industry Forecast, 2024-2033

Description

Intravenous (IV) Hydration Therapy Market

The intravenous (IV) hydration therapy market was valued at $2.3 billion in 2023 and is projected to reach $4.9 billion by 2033, growing at a CAGR of 7.8% from 2024 to 2033.

Intravenous (IV) hydration therapy is the medical procedure in which medications, fluids, vitamins, and electrolytes are infused directly into the bloodstream through a vein. The therapy is a highly effective procedure as it ensures efficient and quick replenishment of essential fluids and nutrients lost due to dehydration. Dehydration is the excessive loss of fluids from the body caused by some illness, excessive alcohol consumption, or intense physical activity. The treatment is applicable in diverse medical settings for the management of chronic conditions, preoperative & postoperative care, and to cure patients with severe infections or gastrointestinal problems.

One of the key drivers of the intravenous (IV) hydration therapy market is increase in uptight lifestyle among individuals with high stress levels. A stressed lifestyle is one of the most common reasons for rising dehydration among individuals. In addition, the geriatric population is growing exponentially across the globe, who are highly susceptible to ailments and hospitalization. This boosts the demand for IV hydration therapy, thus augmenting the market growth. In recent times, the administration of IV therapy as a part of self-care routine or rejuvenation is trending, particularly among celebrities. Moreover, specialized centers called "hydration bars" are being established for people to receive therapy as a form of relaxation.

However, the availability of other alternatives for hydration therapy, such as the oral rehydration solutions restrain the development of the market. Furthermore, the shortage of dedicated medical facilities and well-trained staff, particularly in rural areas, presents challenges for the expansion of the market. On the contrary, advancements in technology and modifications in the conventional formulations administered during treatment are presenting lucrative opportunities for market growth. For instance, personalized solutions are being developed according to the requirements of every individual, hence aiding them to achieve their health goal.

Segment Review

The intravenous (IV) hydration therapy market is segmented into service, component, end user, and region. On the basis of service, the market is divided into immune boosters, energy boosters, skin care, migraine, and others. By component, it is bifurcated into medicated and non-medicated. As per end user, it is categorized into hospital & clinics, wellness centers & spas, home healthcare, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

On the basis of service, the immune boosters segment dominates the market.

By component, the medicated segmented experiences significant demand in the market.

As per end user, the hospital & clinics segment acquires a high share of the market.

Region wise, North America leads the market.

Competition Analysis

The major players operating in the global intravenous (IV) hydration therapy market include Davita, Nikkiso Co. Ltd., Core IV Therapy, LLC, Cryojuvenate UK Ltd., B. Braun Medical Inc., Otsuka Pharmaceutical Co., Ltd., NexGen Health, JW Life Science Corporation, Amanta Healthcare Limited., and Baxter International Inc. These players have adopted various key developmental strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the market.

Additional benefits you will get with this purchase are:

Quarterly Update and* (only available with a corporate license, on listed price)
5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
Free Upcoming Version on the Purchase of Five and Enterprise User License.
16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
Free data Pack on the Five and Enterprise User License. (Excel version of the report)
Free Updated report if the report is 6-12 months old or older.
24-hour priority response*
Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

Regulatory Guidelines
Additional company profiles with specific to client's interest
Expanded list for Company Profiles
Historic market data
Reimbursement Scenario

Key Market Segments

By Service

Immune boosters
Energy boosters
Skin care
Migraine
Others

By Component

Medicated
Non-medicated

By End User

Hospital clinics
Wellness centers spas
Home healthcare
Others

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- France
- Germany
- Italy
- Spain
- UK
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
LAMEA
- Brazil
- South Africa
- Saudi Arabia
- Rest of LAMEA

Key Market Players:

Davita
Nikkiso Co. Ltd.
Core IV Therapy, LLC
Cryojuvenate UK Ltd.
B. Braun Medical Inc.
Otsuka Pharmaceutical Co., Ltd.
NexGen Health
JW Life Science Corporation
Amanta Healthcare Limited.
Baxter International Inc.?

Product Code: A323708

CHAPTER 1: INTRODUCTION

1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
- 1.4.1. Primary Research
- 1.4.2. Secondary Research
- 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

3.1. Market Definition and Scope
3.2. Key Findings
- 3.2.1. Top Investment Pockets
- 3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
- 3.3.1. Bargaining Power of Suppliers
- 3.3.2. Threat of New Entrants
- 3.3.3. Threat of Substitutes
- 3.3.4. Competitive Rivalry
- 3.3.5. Bargaining Power among Buyers
3.5. Market Dynamics
- 3.5.1. Drivers
- 3.5.2. Restraints
- 3.5.3. Opportunities

CHAPTER 4: INTRAVENOUS (IV) HYDRATION THERAPY MARKET, BY SERVICE

4.1. Market Overview
- 4.1.1 Market Size and Forecast, By Service
4.2. Immune Boosters
- 4.2.1. Key Market Trends, Growth Factors and Opportunities
- 4.2.2. Market Size and Forecast, By Region
- 4.2.3. Market Share Analysis, By Country
4.3. Energy Boosters
- 4.3.1. Key Market Trends, Growth Factors and Opportunities
- 4.3.2. Market Size and Forecast, By Region
- 4.3.3. Market Share Analysis, By Country
4.4. Skin Care
- 4.4.1. Key Market Trends, Growth Factors and Opportunities
- 4.4.2. Market Size and Forecast, By Region
- 4.4.3. Market Share Analysis, By Country
4.5. Migraine
- 4.5.1. Key Market Trends, Growth Factors and Opportunities
- 4.5.2. Market Size and Forecast, By Region
- 4.5.3. Market Share Analysis, By Country
4.6. Others
- 4.6.1. Key Market Trends, Growth Factors and Opportunities
- 4.6.2. Market Size and Forecast, By Region
- 4.6.3. Market Share Analysis, By Country

CHAPTER 5: INTRAVENOUS (IV) HYDRATION THERAPY MARKET, BY COMPONENT

5.1. Market Overview
- 5.1.1 Market Size and Forecast, By Component
5.2. Medicated
- 5.2.1. Key Market Trends, Growth Factors and Opportunities
- 5.2.2. Market Size and Forecast, By Region
- 5.2.3. Market Share Analysis, By Country
5.3. Non-medicated
- 5.3.1. Key Market Trends, Growth Factors and Opportunities
- 5.3.2. Market Size and Forecast, By Region
- 5.3.3. Market Share Analysis, By Country

CHAPTER 6: INTRAVENOUS (IV) HYDRATION THERAPY MARKET, BY END USER

6.1. Market Overview
- 6.1.1 Market Size and Forecast, By End User
6.2. Hospital Clinics
- 6.2.1. Key Market Trends, Growth Factors and Opportunities
- 6.2.2. Market Size and Forecast, By Region
- 6.2.3. Market Share Analysis, By Country
6.3. Wellness Centers Spas
- 6.3.1. Key Market Trends, Growth Factors and Opportunities
- 6.3.2. Market Size and Forecast, By Region
- 6.3.3. Market Share Analysis, By Country
6.4. Home Healthcare
- 6.4.1. Key Market Trends, Growth Factors and Opportunities
- 6.4.2. Market Size and Forecast, By Region
- 6.4.3. Market Share Analysis, By Country
6.5. Others
- 6.5.1. Key Market Trends, Growth Factors and Opportunities
- 6.5.2. Market Size and Forecast, By Region
- 6.5.3. Market Share Analysis, By Country

CHAPTER 7: INTRAVENOUS (IV) HYDRATION THERAPY MARKET, BY REGION

7.1. Market Overview
- 7.1.1 Market Size and Forecast, By Region
7.2. North America
- 7.2.1. Key Market Trends and Opportunities
- 7.2.2. Market Size and Forecast, By Service
- 7.2.3. Market Size and Forecast, By Component
- 7.2.4. Market Size and Forecast, By End User
- 7.2.5. Market Size and Forecast, By Country
- 7.2.6. U.S. Intravenous (IV) Hydration Therapy Market
  - 7.2.6.1. Market Size and Forecast, By Service
  - 7.2.6.2. Market Size and Forecast, By Component
  - 7.2.6.3. Market Size and Forecast, By End User
- 7.2.7. Canada Intravenous (IV) Hydration Therapy Market
  - 7.2.7.1. Market Size and Forecast, By Service
  - 7.2.7.2. Market Size and Forecast, By Component
  - 7.2.7.3. Market Size and Forecast, By End User
- 7.2.8. Mexico Intravenous (IV) Hydration Therapy Market
  - 7.2.8.1. Market Size and Forecast, By Service
  - 7.2.8.2. Market Size and Forecast, By Component
  - 7.2.8.3. Market Size and Forecast, By End User
7.3. Europe
- 7.3.1. Key Market Trends and Opportunities
- 7.3.2. Market Size and Forecast, By Service
- 7.3.3. Market Size and Forecast, By Component
- 7.3.4. Market Size and Forecast, By End User
- 7.3.5. Market Size and Forecast, By Country
- 7.3.6. France Intravenous (IV) Hydration Therapy Market
  - 7.3.6.1. Market Size and Forecast, By Service
  - 7.3.6.2. Market Size and Forecast, By Component
  - 7.3.6.3. Market Size and Forecast, By End User
- 7.3.7. Germany Intravenous (IV) Hydration Therapy Market
  - 7.3.7.1. Market Size and Forecast, By Service
  - 7.3.7.2. Market Size and Forecast, By Component
  - 7.3.7.3. Market Size and Forecast, By End User
- 7.3.8. Italy Intravenous (IV) Hydration Therapy Market
  - 7.3.8.1. Market Size and Forecast, By Service
  - 7.3.8.2. Market Size and Forecast, By Component
  - 7.3.8.3. Market Size and Forecast, By End User
- 7.3.9. Spain Intravenous (IV) Hydration Therapy Market
  - 7.3.9.1. Market Size and Forecast, By Service
  - 7.3.9.2. Market Size and Forecast, By Component
  - 7.3.9.3. Market Size and Forecast, By End User
- 7.3.10. UK Intravenous (IV) Hydration Therapy Market
  - 7.3.10.1. Market Size and Forecast, By Service
  - 7.3.10.2. Market Size and Forecast, By Component
  - 7.3.10.3. Market Size and Forecast, By End User
- 7.3.11. Rest of Europe Intravenous (IV) Hydration Therapy Market
  - 7.3.11.1. Market Size and Forecast, By Service
  - 7.3.11.2. Market Size and Forecast, By Component
  - 7.3.11.3. Market Size and Forecast, By End User
7.4. Asia-Pacific
- 7.4.1. Key Market Trends and Opportunities
- 7.4.2. Market Size and Forecast, By Service
- 7.4.3. Market Size and Forecast, By Component
- 7.4.4. Market Size and Forecast, By End User
- 7.4.5. Market Size and Forecast, By Country
- 7.4.6. China Intravenous (IV) Hydration Therapy Market
  - 7.4.6.1. Market Size and Forecast, By Service
  - 7.4.6.2. Market Size and Forecast, By Component
  - 7.4.6.3. Market Size and Forecast, By End User
- 7.4.7. Japan Intravenous (IV) Hydration Therapy Market
  - 7.4.7.1. Market Size and Forecast, By Service
  - 7.4.7.2. Market Size and Forecast, By Component
  - 7.4.7.3. Market Size and Forecast, By End User
- 7.4.8. India Intravenous (IV) Hydration Therapy Market
  - 7.4.8.1. Market Size and Forecast, By Service
  - 7.4.8.2. Market Size and Forecast, By Component
  - 7.4.8.3. Market Size and Forecast, By End User
- 7.4.9. South Korea Intravenous (IV) Hydration Therapy Market
  - 7.4.9.1. Market Size and Forecast, By Service
  - 7.4.9.2. Market Size and Forecast, By Component
  - 7.4.9.3. Market Size and Forecast, By End User
- 7.4.10. Australia Intravenous (IV) Hydration Therapy Market
  - 7.4.10.1. Market Size and Forecast, By Service
  - 7.4.10.2. Market Size and Forecast, By Component
  - 7.4.10.3. Market Size and Forecast, By End User
- 7.4.11. Rest of Asia-Pacific Intravenous (IV) Hydration Therapy Market
  - 7.4.11.1. Market Size and Forecast, By Service
  - 7.4.11.2. Market Size and Forecast, By Component
  - 7.4.11.3. Market Size and Forecast, By End User
7.5. LAMEA
- 7.5.1. Key Market Trends and Opportunities
- 7.5.2. Market Size and Forecast, By Service
- 7.5.3. Market Size and Forecast, By Component
- 7.5.4. Market Size and Forecast, By End User
- 7.5.5. Market Size and Forecast, By Country
- 7.5.6. Brazil Intravenous (IV) Hydration Therapy Market
  - 7.5.6.1. Market Size and Forecast, By Service
  - 7.5.6.2. Market Size and Forecast, By Component
  - 7.5.6.3. Market Size and Forecast, By End User
- 7.5.7. South Africa Intravenous (IV) Hydration Therapy Market
  - 7.5.7.1. Market Size and Forecast, By Service
  - 7.5.7.2. Market Size and Forecast, By Component
  - 7.5.7.3. Market Size and Forecast, By End User
- 7.5.8. Saudi Arabia Intravenous (IV) Hydration Therapy Market
  - 7.5.8.1. Market Size and Forecast, By Service
  - 7.5.8.2. Market Size and Forecast, By Component
  - 7.5.8.3. Market Size and Forecast, By End User
- 7.5.9. Rest of LAMEA Intravenous (IV) Hydration Therapy Market
  - 7.5.9.1. Market Size and Forecast, By Service
  - 7.5.9.2. Market Size and Forecast, By Component
  - 7.5.9.3. Market Size and Forecast, By End User

CHAPTER 8: COMPETITIVE LANDSCAPE

8.1. Introduction
8.2. Top Winning Strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top Player Positioning, 2023

CHAPTER 9: COMPANY PROFILES

9.1. Davita
- 9.1.1. Company Overview
- 9.1.2. Key Executives
- 9.1.3. Company Snapshot
- 9.1.4. Operating Business Segments
- 9.1.5. Product Portfolio
- 9.1.6. Business Performance
- 9.1.7. Key Strategic Moves and Developments
9.2. Nikkiso Co. Ltd.
- 9.2.1. Company Overview
- 9.2.2. Key Executives
- 9.2.3. Company Snapshot
- 9.2.4. Operating Business Segments
- 9.2.5. Product Portfolio
- 9.2.6. Business Performance
- 9.2.7. Key Strategic Moves and Developments
9.3. Core IV Therapy, LLC
- 9.3.1. Company Overview
- 9.3.2. Key Executives
- 9.3.3. Company Snapshot
- 9.3.4. Operating Business Segments
- 9.3.5. Product Portfolio
- 9.3.6. Business Performance
- 9.3.7. Key Strategic Moves and Developments
9.4. Cryojuvenate UK Ltd.
- 9.4.1. Company Overview
- 9.4.2. Key Executives
- 9.4.3. Company Snapshot
- 9.4.4. Operating Business Segments
- 9.4.5. Product Portfolio
- 9.4.6. Business Performance
- 9.4.7. Key Strategic Moves and Developments
9.5. B. Braun Medical Inc.
- 9.5.1. Company Overview
- 9.5.2. Key Executives
- 9.5.3. Company Snapshot
- 9.5.4. Operating Business Segments
- 9.5.5. Product Portfolio
- 9.5.6. Business Performance
- 9.5.7. Key Strategic Moves and Developments
9.6. Otsuka Pharmaceutical Co., Ltd.
- 9.6.1. Company Overview
- 9.6.2. Key Executives
- 9.6.3. Company Snapshot
- 9.6.4. Operating Business Segments
- 9.6.5. Product Portfolio
- 9.6.6. Business Performance
- 9.6.7. Key Strategic Moves and Developments
9.7. NexGen Health
- 9.7.1. Company Overview
- 9.7.2. Key Executives
- 9.7.3. Company Snapshot
- 9.7.4. Operating Business Segments
- 9.7.5. Product Portfolio
- 9.7.6. Business Performance
- 9.7.7. Key Strategic Moves and Developments
9.8. JW Life Science Corporation
- 9.8.1. Company Overview
- 9.8.2. Key Executives
- 9.8.3. Company Snapshot
- 9.8.4. Operating Business Segments
- 9.8.5. Product Portfolio
- 9.8.6. Business Performance
- 9.8.7. Key Strategic Moves and Developments
9.9. Amanta Healthcare Limited.
- 9.9.1. Company Overview
- 9.9.2. Key Executives
- 9.9.3. Company Snapshot
- 9.9.4. Operating Business Segments
- 9.9.5. Product Portfolio
- 9.9.6. Business Performance
- 9.9.7. Key Strategic Moves and Developments
9.10. Baxter International Inc.?
- 9.10.1. Company Overview
- 9.10.2. Key Executives
- 9.10.3. Company Snapshot
- 9.10.4. Operating Business Segments
- 9.10.5. Product Portfolio
- 9.10.6. Business Performance
- 9.10.7. Key Strategic Moves and Developments